Driehaus Life Sciences Fund, Ltd.
Raised
$28M
Investors
12
Min Invest
$1,000,000
Is this your company or fund? Claim this page free.
AltStreet Analysis
·Generated from EDGAR primary sources
Driehaus Life Sciences Fund, Ltd. is a Cayman Islands-domiciled pooled investment fund managed by Driehaus Capital Management LLC, raising capital under Rule 506(b) and 3(c)(1). This amended filing reports $28.4M sold to 12 investors with a $1.0M minimum investment. The fund focuses on longevity and biotech strategies.
This longevity_biotech vehicle employs the standard 506(b)/3(c)(1) exemption structure for private investment funds with a $1.0M minimum, positioning it in the institutional-to-qualified-purchaser tier. The per-investor average of approximately $2.4M and Cayman domicile are typical for U.S.-managed life sciences funds serving accredited and international investors.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
Capital Raise Timeline
6 Form D filings from Jan 15, 2021 to Jan 16, 2026, the latest a D/A.
In the Terminal
Filing events
5
latest Jan 16, 2026
Critical / warning
0 / 0
1 watch · 4 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
raising
Latest event Sold increase · Jan 16, 2026
SEC.govFund family Part of the Driehaus Life Sciences Fund family: 3 vehicles across 0 generations · full family and the filing behind each link in the terminal
Investor
- The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
- 5 filing events with values and deltas, latest 2026-01-16, and alerts on the next one
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Regulatory Activity
Filing events on this entity detected by AltStreet's EDGAR monitoring.
Signal analysis reserved for subscribers
Severity grading, value-change deltas, and analyst notes on these filings ship in the AltStreet newsletter and the Pro terminal.
Get the signal feedAdviser of Record (Form ADV)
CRD 105757 · SEC-registered adviser · lists this fund on Schedule D 7.B.(1) as a hedge fund
Auditor named on Form ADV: Ernst & Young LLP · PCAOB-registered per the adviser
From the adviser's Form ADV as loaded from the SEC bulk data, joined on this issuer's Form D file number. Fund-level figures and the adviser's full fund roster are in the terminal.
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
n/a Driehaus Capital Management LLC
Promoter · Chicago, IL
Alex Munns
Executive Officer · Chicago, IL
Michael Caldwell
Executive Officer · Chicago, IL
Janet McWilliams
Executive Officer · Chicago, IL
Carrie O'Donnell
Director · Chicago, IL
Rachel Williams
Director · Grand Cayman, E9
Tanya Campbell
Director · Grand Cayman, E9
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Thomas SeftenbergCRD 3127527 on BrokerCheck
Associated broker-dealer: Foreside Financial Services, LLC (CRD 148477) · Chicago, IL · Soliciting in all states
Lee DiamandakisCRD 4144827 on BrokerCheck
Associated broker-dealer: Foreside Financial Services, LLC (CRD 148477) · Chicago, IL · Soliciting in all states
Questions About Driehaus Life Sciences Fund, Ltd.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Driehaus Life Sciences Fund, Ltd.?
Driehaus Life Sciences Fund, Ltd. is a Cayman Islands entity that filed a Form D with the SEC on January 16, 2026 as a hedge fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(1) for an offering of pooled investment fund interests. AltStreet links the issuer to Driehaus Life Sciences Fund, Ltd..
Is Driehaus Life Sciences Fund, Ltd. legit?
AltStreet does not rate legitimacy; it reports the public record. Driehaus Life Sciences Fund, Ltd. filed a Form D with the SEC on January 16, 2026 claiming Rule 506(b), Section 3(c), Section 3(c)(1). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $28,376,492 sold to 12 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. The issuer is linked to Driehaus Life Sciences Fund, Ltd., which AltStreet has reviewed. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Driehaus Life Sciences Fund, Ltd. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Driehaus Life Sciences Fund, Ltd. claimed Rule 506(b), Section 3(c), Section 3(c)(1) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Driehaus Life Sciences Fund, Ltd. raised?
Driehaus Life Sciences Fund, Ltd. reported $28,376,492 sold from 12 investors in an offering of indefinite size as of the Form D filed January 16, 2026.
Who can invest in Driehaus Life Sciences Fund, Ltd.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(1), it may have no more than 100 beneficial owners. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $1,000,000.
What is the minimum investment in Driehaus Life Sciences Fund, Ltd.?
The Form D lists $1,000,000 as the minimum investment accepted from any outside investor as of January 16, 2026. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling Driehaus Life Sciences Fund, Ltd. and how are they paid?
The Form D names Thomas Seftenberg (CRD 3127527), associated with Foreside Financial Services, LLC; Lee Diamandakis (CRD 4144827), associated with Foreside Financial Services, LLC as recipients of sales compensation soliciting in all states. Sales commissions are reported as $198,351 and finders' fees as $0. Form D allows these to be estimates.
Who is behind Driehaus Life Sciences Fund, Ltd.?
The Form D lists 7 related persons: Driehaus Capital Management LLC, promoter (Investment Adviser); Alex Munns, executive officer (Assistant Portfolio Manager); Michael J. Caldwell, executive officer (Portfolio Manager); Janet J. McWilliams, executive officer; Carrie J. O'Donnell, director; Rachel J. Williams, director; Tanya J. Campbell, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Driehaus Life Sciences Fund, Ltd. located?
The issuer's address on its SEC filings is Maples Corporate Services Limited, Ugland House, South Church Street, Grand Cayman, Cayman Islands KY1-1104. Its phone number of record is 345-949-8066. It is organized under the laws of Cayman Islands.
How long is the Driehaus Life Sciences Fund, Ltd. offering open?
The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 5 amendments are on record for this CIK.
How large is Driehaus Life Sciences Fund, Ltd.?
The issuer declined to disclose its net asset value range on the Form D, which the form permits.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Platform verification: the separate analyst-reviewed program for platforms, with right of reply and a document library.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.